Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
A PHASE II STUDY Of ADJUVANT CHEMOTHERAPY After SURGERY For STAGE I Lung ADENOCARCINOMA PATIENTS With MICROPAPILLARY COMPONENT More Than Or EQUAL To 20%
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Listed as NCT03351842, this PHASE2 trial focuses on Chemotherapy, Adjuvant and Histological Type of Neoplasm and remains actively recruiting participants. Sponsored by Shanghai Pulmonary Hospital, Shanghai, China, it has been updated 6 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE2
First recorded
Sep 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Pulmonary Hospital, Shanghai, China
For direct contact, visit the study record on ClinicalTrials.gov .